Please use this identifier to cite or link to this item:
|Title:||Investigation of novel bis- and tris-tetraazamacrocycles for use in the copper-64 (Cu-64) radiolabeling of antibodies with potential to increase the therapeutic index for drug targeting.|
|Publisher:||American Chemical Society|
|Citation:||Ramli, M., Smith, S. V., & Lindoy, L. F. (2009). Investigation of novel bis- and tris-tetraazamacrocycles for use in the copper-64 (Cu-64) radiolabeling of antibodies with potential to increase the therapeutic index for drug targeting. Bioconjugate Chemistry, 20(5), 868-876. doi:10.1021/bc800337d|
|Abstract:||The 64Cu complexes of a series of mono-, bis-, and tris-tetraazamacrocycles have been prepared, and their stability in human sera has been assessed. The ligands forming the most stable Cu2+ complexes were then conjugated to the B72.3 antibody (mAb). Conditions for conjugation of the ligands to the mAb were optimized for the concentration of protein, ligand, pH, temperature, and time. The optimum moles of Cu2+ attached to the mAb were as high as 3.5 for L2 and 5.5 or 2.7 for L5, and the immunoreactivity was ≥80%. Biodistribution of the radioimmunoconjugates showed good tumor localization and target-to-background ratios that were significantly enhanced compared to those achieved with monotetraazamacrocyclic derivatives. © 2009, American Chemical Society|
|Gov't Doc #:||1607|
|Appears in Collections:||Journal Articles|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.